Adult cardiac surgery is often complicated by elevated blood losses that account for elevated transfusion requirements. Perioperative bleeding and transfusion of blood products are major risk factors for morbidity and mortality. Timely diagnostic and goal-directed therapies aim at the reduction of bleeding and need for allogeneic transfusions. Single-centre, prospective, randomized trial assessing blood loss and transfusion requirements of 26 adult patients undergoing elective cardiac surgery at high risk for perioperative bleeding. Primary endpoint was blood loss at 24 h postoperatively. Random assignment to intra- and postoperative haemostatic management following either an algorithm based on conventional coagulation assays (conventional group: platelet count, aPTT, PT, fibrinogen) or based on point-of-care (PoC-group) monitoring, i.e. activated rotational thromboelastometry (ROTEM®) combined with multiple aggregometry (Multiplate®). Differences between groups were analysed using nonparametric tests for independent samples. The study was terminated after interim analysis (n = 26). Chest tube drainage volume was 360 ml (IQR 229-599 ml) in the conventional group, and 380 ml (IQR 310-590 ml) in the PoC-group (p = 0.767) after 24 h. Basic patient characteristics, results of PoC coagulation assays, and transfusion requirements of red blood cells and fresh frozen plasma did not differ between groups. Coagulation results were comparable. Platelets were transfused in the PoC group only. Blood loss via chest tube drainage and transfusion amounts were not different comparing PoC- and central lab-driven transfusion algorithms in subjects that underwent high-risk cardiac surgery. Routine PoC coagulation diagnostics do not seem to be beneficial when actual blood loss is low. High risk procedures might not suffice as a sole risk factor for increased blood loss. NCT01402739 , Date of registration July 26, 2011.
General (GA)- and epidural-anesthesia may cause a drop in body-core-temperature (BCTdrop), and hypothermia, which may alter tissue oxygenation (StO2) and microperfusion after cytoreductive surgery for ovarian cancer. Cell metabolism of subcutaneous fat- or skeletal muscle cells, measured in microdialysis, may be affected. We hypothesized that forced-air prewarming during epidural catheter placement and induction of GA maintains normothermia and improves microperfusion. After ethics approval 47 women scheduled for cytoreductive surgery were prospectively enrolled. Women in the study group were treated with a prewarming of 43 °C during epidural catheter placement. BCT (Spot on®, 3 M) was measured before (T1), after induction of GA (T2) at 15 min (T3) after start of surgery, and until 2 h after ICU admission (TICU2h). Primary endpoint was BCTdrop between T1 and T2. Microperfusion-, hemodynamic- and clinical outcomes were defined as secondary outcomes. Statistical analysis used the Mann-Whitney-U- and non-parametric-longitudinal tests. BCTdrop was 0.35 °C with prewarming and 0.9 °C without prewarming (p < 0.005) and BCT remained higher over the observation period (ΔT4 = 0.9 °C up to ΔT7 = 0.95 °C, p < 0.001). No significant differences in hemodynamic parameters, transfusion, arterial lactate and dCO2 were measured. In microdialysis the ethanol ratio was temporarily, but not significantly, reduced after prewarming. Lactate, glucose and glycerol after PW tended to be more constant over the entire period. Postoperatively, six women without prewarming, but none after prewarming were mechanical ventilated (p < 0.001). Prewarming at 43 °C reduces the BCTdrop and maintains normothermia without impeding the perioperative routine patient flow. Microdialysis indicate better preserved parameters of microperfusion. ClinicalTrials.gov ; ID: NCT02364219 ; Date of registration: 18-febr-2015.
Das zunehmende Verständnis des Phänomens der traumainduzierten Koagulopathie hat zu einer Erweiterung der Therapiestrategien bei der akuten Versorgung polytraumatisierter Patienten geführt. Der Artikel gibt einen Überblick über die aktuellen Empfehlungen zur Therapie basierend auf einer Übersicht der aktuellen Literatur mit besonderer Berücksichtigung der gültigen Leitlinien. Die traumainduzierte Koagulopathie ist ein eigenständiges hochakutes multifaktorielles Krankheitsbild mit signifikantem Einfluss auf die Mortalität schwerstverletzter Patienten. Maßgeblich verantwortlich für das Auftreten und die Ausprägung scheint neben dem Gewebetrauma eine schockbedingte Gewebsminderperfusion zu sein. Verstärkt wird die Koagulopathie durch begleitende Faktoren wie Hypothermie oder Dilution. Diagnose und Therapie einer traumainduzierten Koagulopathie müssen so früh wie möglich beginnen. Standardgerinnungslaborparameter sind bei der Diagnosefindung nur eingeschränkt hilfreich. Die Therapie erfolgt nach dem Konzept der Damage-Control-Resuscitation. Die Substitution großer Mengen an Volumen sollte vermieden und ein mittlerer arterieller Druck von 65mmHg (unter Berücksichtigung der Kontraindikationen!) angestrebt werden. Ein spezifisches Massivtransfusionsprotokoll sollte eingeführt und fortgesetzt werden. Eine Azidose sollte vermieden und durch adäquate Therapie des Schocks behandelt werden. Ein Auskühlen des Patienten sollte durch aktives Wärmemanagement verhindert oder therapiert werden. Eine Hypokalzämie<0,9mmol/l sollte vermieden und kann therapiert werden. Bei massiver Blutung kann eine Transfusion mit Erythrozyten ab einem Hb von 10g/dl(6,2mmol/l) begonnen werden.Wird die Gerinnungstherapie bei Massivtransfusionen mit FFP durchgeführt, sollte ein Verhältnis von FFP zu EK im Bereich von 1:2 bis 1:1 angestrebt werden. Zur Behandlung einer Hyperfibrinolyse nach schwerem Trauma sollte frühzeitig der Einsatz von Tranexamsäureerwogen werden. Bei signifikanter Blutung sollte eine Substitution von Fibrinogen ab einer Konzentration von 1,5g/l(4,41μmol/l)erfolgen. Prothrombinkomplexpräparate können bei fortbestehender schwerer Blutung oder antikoagulatorischer Vormedikation hilfreich sein. Die Indikation zur Thrombozytentransfusion kann bei akuter Blutung ab 100000/μl erfolgen. Bei diffus blutenden Patienten mit V.a.Thombozytopathie kann ein Therapieversuch mit Desmopressin in Erwägung gezogen werden.Wenn eine Faktor XIII(FXIII)-Messung nicht zeitnah möglich ist, kann bei schweren akuten Blutungen eine FXIII-Blindgabe erwogen werden.Bei massiver persistierender Blutung kann, nach Ausschöpfung sämtlicher Therapieoptionen und Schaffung optimaler Rahmenbedingungen, im Einzelfall die Applikation vonrekombinantem aktiviertem Faktor VII (rFVIIa) außerhalb der Zulassungsindikation erwogen werden. The increasing understanding of trauma-induced coagulopathy has led to an expansion of treatment strategies in the acute management of trauma patients. The aim of this manuscript is to give a summary of current recommendations for the treatment of trauma-induced coagulopathy based on current literature and valid guidelines. Thetrauma-induced coagulopathyis an independentacutemultifactorial diseasewith significantimpact on the mortalityof severelyinjured patients. Largely responsible for the occurrence and severity of trauma-induced coagulopathy seems to be tissue trauma and shock-induced hypoperfusion. Coagulopathy is amplified by accompanying factors such as hypothermia or dilution. Diagnosis and therapy of deranged coagulation should start as soon as possible. Routinely tested coagulation parameters are of limited use to confirm diagnosis. Therapy follows the concept of "damage control resuscitation". Infusion of large volumes should be avoided and a mean arterial pressure of 65mmHg (in consideration of contraindications!) may be aimed.A specific protocol for massive transfusion should be introduced and continued.Acidaemia should be prevented and treated by appropriate shock therapy.Loss of body temperature should be prevented and treated. Hypocalcaemia <0.9 mmol/l should be avoided and may be treated. For actively bleeding patients, packed red blood cells (pRBC) may be given at haemoglobin<10g/dl(0,62mmol/l). If massive transfusion is performed using fresh frozen plasma (FFP), a ratio of FFP to pRBC of 1:2 to 1:1 should be achieved.For treatment of hyperfibrinolysis after severe trauma the use of tranexamic acid should be considered at an early stage. Fibrinogen should be substituted at levels <1,5g/l (4,41μmol/l). Prothrombin complex concentrates may be helpfull for treatment of diffuse bleeding or anticoagulativemedikation. In acute bleeding, platelets may be transfused at a platet count <100000/μl. For diffuse bleeding or thrombocytopathic patients desmopressin might be a therapeutic option.If a factor XIII (FXIII) measurement is not promptly available, a factor XIII blind-dose should be considered in severe ongoing bleeding. The use of recombinant activated coagulation factor VII (rFVIIa) be considered if major bleeding persists despite standard attempts to control bleeding and best practice use of blood components.